Bennett Baquet, MD
Endocrinology, Diabetes & Metabolism · Lafayette, LANPI 1073563631
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,725 of the $29,950 with a category attached, or 75.9%. Tandem Diabetes Care, Inc. accounts for 75.3% of it on its own, with 52 other manufacturers making up the rest. Reporting peaked in 2021 at $10,634 and has fallen 86.6% since, to $1,426 in 2025.
Across 523 payments — averaging $57.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$23K
- Dexcom, Inc.$2K
- Amgen$915
- Medtronic$405
- AstraZeneca$378
- Novo Nordisk$339
- plus $4K from 47 others
What the payments were for
- Speaking & faculty fees$22,72576%
- Food & beverage$7,19724%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$15,400
- t:slim X2 insulin pump$6,500
- DEXCOM G6 TRANSMITTER$232
- Minimed 770G System$225
How this compares
$29,950 in reported general payments places this provider in the 80th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 660 | $804,041 |
| JardianceEmpagliflozin | 939 | $802,354 |
| MounjaroTirzepatide | 522 | $619,214 |
| TrulicityDulaglutide | 309 | $381,560 |
| Tresiba Flextouch U-100Insulin Degludec | 372 | $253,836 |
| Somatuline DepotLanreotide Acetate | 26 | $204,951 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 187 | $186,033 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 141 | $148,716 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 229 | $145,789 |
| Tresiba Flextouch U-200Insulin Degludec | 117 | $145,456 |
| Novolog FlexpenInsulin Aspart | 337 | $106,352 |
| SomavertPegvisomant | 12 | $97,190 |
| FarxigaDapagliflozin Propanediol | 134 | $93,812 |
| FiaspInsulin Aspart (Niacinamide) | 50 | $60,704 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 386 | $58,588 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev | $309 | $1,017,567843 claims |
| Novo NordiskOzempic, Fiasp, Novolog, Rybelsus | $339 | $934,514910 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr | $114 | $842,174983 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $18 | $204,95126 claims |
| PfizerSomavert, Genotropin | $14 | $138,67534 claims |
| AstraZenecaFarxiga | $378 | $93,812134 claims |
| MerckJanuvia | $202 | $56,53486 claims |
| Radius Health, Inc.Tymlos | $220 | $51,95619 claims |
| AmgenProlia | $915 | $44,93526 claims |
| AbbVieSynthroid | $44 | $38,308575 claims |
| Johnson & JohnsonInvokana | $45 | $37,46549 claims |
| Antares Pharma, Inc.Xyosted | $14 | $37,00842 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Lafayette
- Justin FontenotLafayette$397K
- Ghyass RizkLafayette$16K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Marideli ScanlanMarrero$444K
- Ileana TandronSlidell$205K
- Lane FreyThibodaux$202K
- Laura Kimball RavariBossier City$165K
- Lawrence BlondeNew Orleans$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.